Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 299

The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.

Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease

Open access
Jaturapatporn, Darin, Isaac, Mokhtar Gad El Kareem Nasr, McCleery, Jenny, Tabet, Naji · 2012 · Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Alzheimer's disease (AD) is the most common form of dementia. The incidence of AD rises exponentially with age and its prevalence will increase significantly worldwide in the next few decades. Inflammatory processes have been suspected in the pathogenesis of the disease. OBJECTIVES: To review the efficacy and side effects of aspirin, steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of AD, compared to placebo. SEARCH METHODS: We searched ALOIS: the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 12 April 2011 using the terms: aspirin OR "cyclooxygenase 2 inhibitor" OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR "anti-inflammatory" OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR NSAIDS OR NSAID. ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases (including MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS), numerous trial registries (including national, international and pharmacuetical registries) and grey literature sources. SELECTION CRITERIA: All randomised controlled trials assessing the efficacy of aspirin, steroidal and non-steroidal anti-inflammatory drugs in AD. DATA COLLECTION AND ANALYSIS: One author assessed risk of bias of each study and extracted data. A second author verified data selection. MAIN RESULTS: Our search identified 604 potentially relevant studies. Of these, 14 studies (15 interventions) were RCTs and met our inclusion criteria. The numbers of participants were 352, 138 and 1745 for aspirin, steroid and NSAIDs groups, respectively. One selected study comprised two separate interventions. Interventions assessed in these studies were grouped into four categories: aspirin (three interventions), steroids (one intervention), traditional NSAIDs (six interventions), and selective cyclooxygenase-2 (COX-2) inhibitors (five interventions). All studies were evaluated for internal validity using a risk of bias assessment tool. The risk of bias was low for five studies, high for seven studies, and unclear for two studies.There was no significant improvement in cognitive decline for aspirin, steroid, traditional NSAIDs and selective COX-2 inhibitors. Compared to controls, patients receiving aspirin experienced more bleeding while patients receiving steroid experienced more hyperglycaemia, abnormal lab results and face edema. Patients receiving NSAIDs experienced nausea, vomiting, elevated creatinine, elevated LFT and hypertension. A trend towards higher death rates was observed among patients treated with NSAIDS compared with placebo and this was somewhat higher for selective COX-2 inhibitors than for traditional NSAIDs. AUTHORS' CONCLUSIONS: Based on the studies carried out so far, the efficacy of aspirin, steroid and NSAIDs (traditional NSAIDs and COX-2 inhibitors) is not proven. Therefore, these drugs cannot be recommended for the treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd006378.pub2

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. Zhou, 2004, Effectiveness of polydrug therapy for senile dementia, Chinese Journal of Clinical Rehabilitation, 8, 1214
  2. Aisen, 2008, Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial, Current Alzheimer Research, 5, 73, 10.2174/156720508783884602 · DOI
  3. Aizen, 2005, Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia, The Israel Medical Association Journal, 7, 78
  4. Jeong, 2004, Therapeutic potentials of mefenamic acid for the treatment of Alzheimer's disease, Neurobiology of Aging, 25, S589, 10.1016/S0197-4580(04)81961-4 · doi:10.1016/s0197-4580(04)81961-4
  5. Laughlin, 2006, Efficacy and safety of MPC-7869 (R-flurbiprofen), a Selective AB42-Lowering Agent, in Alzheimer's disease (AD): results of a 12-month phase 2 trial and 1-year follow-on study, Journal of the American Geriatrics Society, 54, S7
  6. Leblhuber F Haller H Steiner K Fuchs D DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial Neurology 2004 1030 · DOI
  7. McIntyre, 2006, MPC-7869 - prostate cancer therapy - treatment of Alzheimer's dementia, Drugs of the Future, 31, 22
  8. Meinert, 2008, Triflusal versus aspirin for the prevention of stroke, Progress in Neurotherapeutics and Neuropsychopharmacology, 3, 13
  9. Nourhashemi, 1998, Non steroidal anti-inflammatory drugs in Alzheimer disease, Presse Medicale, 27, 25
  10. Pomara, 1985, Multiple, single-dose naltrexone administrations fail to effect overall cognitive functioning and plasma cortisol in individuals with probable Alzheimer's disease, Neurobiology of Aging, 6, 233, 10.1016/0197-4580(85)90055-7 · doi:10.1016/0197-4580(85)90055-7
  11. Sainati SM Ingram DM Talwalker S Geis GS Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm, Sweden 2000 180
  12. Simon, 1998, Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor - Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects, Arthritis and Rheumatism, 41, 1591, 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J · doi:10.1002/1529-0131(199809)41:9<1591::aid-art9>3.0.co;2-j
  13. Solomon, 2008, Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis, Circulation, 117, 2104, 10.1161/CIRCULATIONAHA.108.764530 · DOI · Paper page
  14. Stevenson, 2004, A pharmacokinetic, pharmacodynamic, and safety study of celecoxib in subjects with probable Alzheimer's disease, Clinical Research and Regulatory Affairs, 21, 49, 10.1081/CRP-120030034 · DOI
  15. Stoppe, 1996, Prescribing practice with cognition enhancers in outpatient care: Are there differences regarding type of dementia? Results of a representation survey in lower Saxony, Germany, Pharmacopsychiatry, 29, 150, 10.1055/s-2007-979562 · doi:10.1055/s-2007-979562
  16. Tsartsalis, 2011, Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: the use of non-steroidal anti-inflammatory drugs, CNS & Neurological Disorders-Drug Targets, 10, 133, 10.2174/187152711794488629 · doi:10.2174/187152711794488629
  17. Watson, 2004, Rosiglitazone preserves cognitive functions in patients with early Alzheimer's disease, Neurobiology of Aging, 25, 83, 10.1016/S0197-4580(04)80284-7 · doi:10.1016/s0197-4580(04)80284-7
  18. Wisloff, 1996, Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group, British Journal of Haematology, 94, 324, 10.1046/j.1365-2141.1996.d01-1802.x · doi:10.1046/j.1365-2141.1996.d01-1802.x
  19. Wollheim, 2000, Selective Cox-2 inhibition in man - therapeutic breakthrough or cosmetic advance?, Rheumatology, 39, 935, 10.1093/rheumatology/39.9.935 · doi:10.1093/rheumatology/39.9.935
  20. Xia, 2007, Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age, Pediatrics, 120, 594, 10.1542/peds.2007-0486 · DOI
  21. Yaqub, 1999, New horizons in management of Alzheimer's disease, Saudi Medical Journal, 20, 671
  22. Zandi, 2005, Pharmacological strategies for prevention of Alzheimer's disease: the epidemiologic evidence, Research and Practice in Alzheimer's Disease, 10, 200
  23. Zaragoza, 2005, Attitude before COX-2 selective inhibitors, Revista De Investigacion Clinica, 57, 6
  24. Zhai, 2010, Efficacy observation of batroxobin for treatment of vascular cognitive impairment, Chinese Journal of Cerebrovascular Diseases, 7, 73
  25. Aisen, 1996, A pilot study of prednisone in Alzheimer's disease, Dementia, 7, 201
  26. World Health Organisation, 1992, The ICD-10 Classification of Mental and Behavioural disorders: clinical Descriptions and Diagnostic Guidelines
  27. Wilcock, 2006, Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Ab42-lowering agent, in Alzheimers disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study., Alzheimer and Dementia, 2, S81

Cited by

See all 299

Metadata

Authors
Jaturapatporn, D., Isaac, M. G. E. K. N., McCleery, J., & Tabet, N.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2012-02-15
Volume
2012
Issue
2
Pages
CD006378-CD006378
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2117324900
Cited by
299
References
133
FWCI
18.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.